eCTD stands for electronic Common Technical Document, and it is the standardized digital format that pharmaceutical companies use to submit drug approval applications to regulatory agencies around the world. Whether a company is seeking approval for a brand-new medication, a generic version, or a biological product, the eCTD provides a universal structure for organizing and delivering all the required data. The format is managed by the International Council for Harmonisation (ICH) and is now mandatory or becoming mandatory in most major regulatory markets, including the United States and Europe.
What the eCTD Actually Does
Before the eCTD existed, drug companies submitted approval applications as massive paper binders, sometimes filling entire trucks with documents. Each country also had its own format requirements, meaning a company seeking approval in multiple markets had to reorganize the same data over and over again.
The eCTD solves both problems. It replaces paper with a structured electronic package built on XML (a type of code that organizes data) and searchable PDF files. And because the format is internationally standardized, the same core structure works for submissions to the FDA in the United States, the European Medicines Agency, Health Canada, Japan’s PMDA, and dozens of other agencies. A reviewer at any of these agencies can navigate directly to the section they need using bookmarks and hyperlinks rather than flipping through binders.
The Five-Module Structure
Every eCTD submission is organized into five modules. Modules 2 through 5 are identical worldwide, while Module 1 is region-specific because each country has its own administrative and labeling requirements.
- Module 1: Administrative Information. This is the region-specific section. It contains cover letters, application forms, proposed labeling, patent information, and any risk management plans required by the local authority.
- Module 2: Summaries. This module gives reviewers a high-level view of the entire submission. It includes overviews of the drug’s quality (how it’s manufactured), its nonclinical data (animal and lab studies), and its clinical data (human trials). Think of it as the executive summary that ties everything together.
- Module 3: Quality. All manufacturing and chemistry data lives here. It covers the drug substance itself (what the active ingredient is, how it’s made, how it’s tested for purity) and the finished drug product (the tablet, injection, or other dosage form, including its packaging and stability over time).
- Module 4: Nonclinical Study Reports. This section contains the full reports from laboratory and animal studies. It covers pharmacology (how the drug works in the body), pharmacokinetics (how the body absorbs, distributes, and eliminates the drug), and toxicology (safety testing for harmful effects).
- Module 5: Clinical Study Reports. The largest module in most submissions, this holds all the data from human clinical trials. It includes everything from early studies on how the drug behaves in healthy volunteers to the large-scale trials that prove the drug is safe and effective for its intended use.
Which Submissions Require eCTD Format
In the United States, the FDA requires eCTD format for all major drug application types submitted to its drug and biologics review centers (CDER and CBER). That includes New Drug Applications (NDAs) for novel medications, Abbreviated New Drug Applications (ANDAs) for generics, Biologics License Applications (BLAs) for biological products, and commercial Investigational New Drug applications (INDs) for products intended for commercial distribution. Master files, such as Drug Master Files that suppliers use to share confidential manufacturing details, also fall under the requirement.
Importantly, even if the original application was filed before these requirements took effect, all subsequent amendments, supplements, and reports for that application must now use the eCTD format.
Version 3.2 vs. Version 4.0
Most submissions worldwide currently use eCTD version 3.2, which has been the workhorse standard for years. Version 4.0 is the next generation, bringing a more modern XML backbone that allows for richer metadata and better lifecycle tracking of documents across multiple submissions.
The FDA completed its technical pilot for version 4.0 in 2023 and began accepting voluntary v4.0 submissions for new applications in September 2024. The mandatory switchover to v4.0 is set for 2029 in the United States. In Europe, the timeline is slightly different: voluntary use for centrally authorized products begins in 2025, with mandatory adoption expected in 2027 for those products and later dates for other procedure types. The latest implementation guide (v1.6) and controlled vocabulary package were endorsed by the ICH Assembly in May 2024.
Technical Requirements for Files
The eCTD isn’t just a folder of random PDFs. Each document must meet specific technical standards. All documents should be in searchable PDF format, meaning reviewers can use text search to find specific terms rather than scrolling through scanned images. When images or other non-text files are included, they should be converted to PDF and retain searchable text whenever possible.
Beyond file format, the entire submission package goes through automated validation before a regulatory agency accepts it. The validation process checks for two levels of problems. A high-severity error is a serious technical issue that prevents the agency from processing the submission at all. If your submission triggers one, it’s considered “not received,” and you have to fix the problem and resubmit. A warning-level error flags something that could affect reviewability but doesn’t automatically block acceptance. The submission will likely be considered received, but review staff may follow up on the issue.
Getting validation right matters because a failed submission can delay a drug’s approval timeline by weeks or months, depending on how quickly the errors are corrected and the package is resubmitted.
Why the Format Matters Beyond Compliance
The eCTD isn’t just a regulatory checkbox. It creates real operational benefits for both the companies submitting applications and the agencies reviewing them. For reviewers, the structured format with XML navigation, bookmarks, and internal hyperlinks means they can jump directly to the data they need instead of searching through thousands of pages. For pharmaceutical companies, the standardized structure means submission teams can build reusable templates, track document versions across a product’s entire regulatory lifecycle, and coordinate filings to multiple countries from a single organized dataset.
The environmental impact is also significant. Before electronic submissions, a single major drug application could run to hundreds of thousands of pages. Multiply that across every drug in development worldwide, and the shift to eCTD has eliminated an enormous volume of paper production, printing, and physical shipping.